Skip to main content
. 2021 Sep 14;2021(9):CD010216. doi: 10.1002/14651858.CD010216.pub6

Polosa 2014b.

Study characteristics
Methods Design: Prospective cohort study
Recruitment: Volunteers, leaflets, cessation service kiosk in hospital
Setting: Smoking cessation clinic, Italy
Study start date: January 2013; Study end date: November 2013
Participants Total N: 50
Inclusion criteria:
  • Healthy people who smoke

  • 18 – 60 years old

  • Smoking ≥ 15 conventional cpd for at least 10 years

  • Unwilling to quit


Exclusion criteria:
  • none stated


40% women, mean age 41, mean cpd 25, mean FTND 6.0
No EC use at baseline, not motivated to quit
Interventions EC: Refillable
2nd generation devices (personal vaporisers ‐ PVs): EGO/CE4 model, filled with tobacco aroma e‐Liquid containing 9 mg/ml nicotine; instructed to use the study products ad libitum (up to a maximum of 5 ml/day; i.e. half vial)
Behavioural support:
Participants were instructed how to charge, fill, activate and use the EC. Key troubleshooting was addressed and phone numbers were supplied for assistance. “No emphasis on encouragement, motivation and reward for the smoking cessation‐related efforts were provided during the study.”
Outcomes 4, 8, 12 and 24 weeks
30‐day PP verified by CO ≤ 10 ppm
Adverse events
Cpd, exhaled CO, reduction rates, product usage, and opinions of the EC products
Study funding "The authors wish to thank FlavourArt (Oleggio, NO, Italy; www.flavourart.it). Authors wish to thank LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League) for supporting this research"
Author declarations "RP has received lecture fees and research funding from Pfizer and GlaxoSmithKline, manufacturers of stop smoking medications. He has also served as a consultant for Pfizer and Arbi Group Srl, an Italian distributor of e‐Cigarettes. RP is currently scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti Smoking League). PC, MM, JBM, and CR have no relevant competing interest to declare in relation to this
work"
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) High risk Not controlled
Allocation concealment (selection bias) High risk Not controlled
Incomplete outcome data (attrition bias)
All outcomes Low risk 76% followed up, ITT analysis used, no significant differences in baseline characteristics between completers and those lost to follow‐up
Selective reporting (reporting bias) Unclear risk Unable to determine prespecified outcomes